Discover Amylyx stock forecasts and price targets for 2023+ through our advanced stock calculator, using the Fibonacci series and the golden ratio, along with consensus predictions and expert analysis from fundamental outlooks.
As we look to emerging medical breakthroughs, Amylyx Pharmaceuticals is at the forefront of innovative solutions for devastating neurological diseases.
We can expect a better future for Amylyx stock as the company has received FDA approval and is rapidly expanding into the market with promising treatments available.
In the current situation, the pharmaceutical industry is considered safe for investment even due to the fear of recession amid rising inflation.
In this post, we’ll explore a data-driven analysis of Amylyx’s stock forecast and price target for 2023 and beyond, using cutting-edge methods to provide unique insight into this exciting opportunity.
You can also see how meaningful the Amylyx Stock Forecast 2022 was last year.
Amylyx Stock
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing unique treatments for neurodegenerative diseases, specifically ALS.
Amylyx company was founded in 2013 and its IPO came in January 2022. Amylyx stock ticker symbol is AMLX.
Fundamentals of Amylyx Stock
Annual result data shows that the financial position of the company is still weak with fragile margins and insufficient levels of profitability.
Despite having minimal debt, the future prospects of the company are uncertain due to negative ROA and ROE.
Analysts have also regularly cut their EPS expectations over the past 12 months.
| Financial Stats | Value |
| AMLX stock price Apr 13 2023 | $30.58 |
| Market Cap | 2.04B |
| 52 Week Range | 6.51-41.93 |
| EPS (TTM) | -3.45 |
| Enterprise Value | 1.61B |
| Price/Book (mrq) | 5.74 |
| EV/EBITDA | -8.03 |
| Total Debt/Equity (mrq) | 1.84 |
Data Source: Yahoo Finance
Amylyx Chart Analysis
AMLX Stock on Monthly Chart
On the monthly chart of Amylyx stock, there is insufficient data for long term analysis as the stock only went public in January 2022.
AMLX Stock on Weekly Chart
From the above weekly chart we can draw the following important conclusions –
- AMLX stock is still in a downtrend.
- The trendlines suggest two important levels of support and resistance at $26 and $32.70, respectively.
- AMLX share price must close above the 20-period SMA (now $34.50) on the weekly chart to start an uptrend.
- Keep watching the charts for positive cross-overs on MACD and Stochastic Momentum Index for better investment opportunities.
Amylyx Stock on Daily Chart
The stock is in an uptrend recently on the daily chart. The stock price is trading above the 20-day SMA with a positive cross-over on the MACD and Stochastic Momentum Index.
These are positive signs for a stock to go up for the short term. But these trends are likely to change on a daily basis. That’s why we should watch the charts closely.
Now it is the turn of Amylyx stock forecast. This forecast will provide you various technical levels for investment or trading which makes your investment more secure.
This is not advice or recommendation. This will be for your learning only. But first of all know the opinion of some experts.
AMLX Stock Forecast 2023 From Expert View
Amylyx’s Relyvrio drug has already received approval from the US FDA for the treatment of neurogenerative disease (ALS).
Due to which Citigroup analyst Neena Bitritto-Garg has raised the target of Amylyx stock price from $48 to $50.
Analyst at Goldman Sachs recommends a hold on the stock with a target of $40.
Analysts at SVB Leerink, Evercore ISI Group and HC Wainwright & Co continue to have buy advice on the stock.
According to CNNdotcom 5 analysts offering forecasts for Amylyx stock have a high estimate of 51.00 and a low estimate of 41.00.
Significance of Amylyx Stock Forecast 2022
Last year, despite limited data, we discussed not buying Amylyx stock between $17 and $21, according to the stock calculator.
You can see on the actual chart that the stock made a 2022 low of $6.51 and a high of $39.77, very close to the predicted levels for the Uptrend Target2 and Downtrend Target4.
| Target1 | Target2 | Target3 | Target4 | |
| above 23 UPTREND Targets | 28 | 38 | 62 | 136 |
| below 19 DOWNTREND Targets | 16 | 13 | 10 | 6 |
Amylyx Stock Forecast 2023
The stock market calculator estimates the AMLX price volatility of 1.142203235 and a No Buy zone between 32 and 38. If one buys above 40 then the stop-loss level should be 35.
| Target1 | Target2 | Target3 | Target4 | |
| above 40 Targets could be | 46 | 58 | 82 | 143 |
| below 30.60 Targets could be | 26 | 21 | 15 | 9 |
Amylyx Stock Forecast 2024
| Target1 | Target2 | Target3 | Target4 | |
| above 44 Targets could be | 54 | 73 | 120 | 268 |
| below 30 Targets could be | 24 | 18 | 11 | 5 |
Amylyx Stock Forecast 2025
| Target1 | Target2 | Target3 | Target4 | |
|---|---|---|---|---|
| above 44 Targets could be | 54 | 74 | 124 | 281 |
| below 30 Targets could be | 24 | 17 | 11 | 5 |
AMLX stock predictions for 2024 and 2025 clearly show no significant difference. Well, this is just a probability and no one knows the future.
Final Thoughts
Amylyx Pharmaceuticals is slowly expanding into the neurodegenerative disease market with FDA approval.
Despite weak financials and a decline in the stock, analysts have mixed recommendations with price targets of $40-$50. The no buy zone is estimated between 32-38 by the stock market calculator.
As Amylyx Pharmaceuticals continues to develop innovative solutions for neurological diseases, it remains a stock to watch in the pharmaceutical industry.
Hi readers, I’d love to hear your thoughts on this pharma stock. Have you conducted any fundamental analysis on it? Please feel free to share your insights in the comments below.
FAQs on AMLX Stock & Forecast
When did Amylyx go public?
Amylyx Pharmaceuticals, Inc. (AMLX) went public on January 07, 2022. The Amylyx IPO was priced at $18-$20. And the stock made a high of $21 and a low of $17.45 on the day of listing.
Who is the CEO of Amylyx?
According to amylyxdotcom, Mr. Joshua B. Cohen and Mr. Justin B. Klee is the Co-Founder and Co-CEO of Amylyx Pharmaceuticals, Inc.
Is Amylyx a good stock to buy?
Because Amylyx is a commercial-stage biotechnology company, it also has FDA approval on certain products for the treatment of ALS and neurodegenerative diseases. So the future of the company can be better.
But right now the financial condition of the company cannot be said to be so good. That's why keeping in mind the technical levels it can be profitable to buy the stock for 2023 with a stoploss of $35 when it moves above $40.
What is the target for Amylyx stock in 2023?
According to the stock market calculator, if AMLX stock price goes above $40 in 2023, the next targets could be 46-58-82 and 143. But conversely, if the price breaks below $30.60, the target could be 26-21-15 and 9.
Keep in mind that this is a mathematical probability and not a suggestion.
